


BIBS 39

Cat. No.:	HY-19732		
CAS No.:	133085-33-3		
Molecular Formula:	C ₃₂ H ₃₆ N ₄ O ₃		
Molecular Weight:	524.65		
Target:	Angiotensin Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 32 mg/mL (60.99 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9060 mL	9.5302 mL	19.0603 mL
	5 mM	0.3812 mL	1.9060 mL	3.8121 mL
	10 mM	0.1906 mL	0.9530 mL	1.9060 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: 1.25 mg/mL (2.38 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 1.25 mg/mL (2.38 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 1.25 mg/mL (2.38 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BIBS 39 is a new nonpeptide angiotensin II (All) receptor antagonist. Target: Angiotensin Receptor in vitro: BIBS 39 displaces [125I] All from its specific binding sites with a K_i value of 29 ± 7 nM for the All subtype 1 (AT1) receptor and a K_i value of 480 ± 110 nM for the All subtype 2 (AT2) receptor. BIBS 222 shows a K_i value of 20 ± 7 nM for the AT1 subtype and a K_i value of 730 ± 170 nM for the AT2 subtype. BIBS 39 is 17 times more selective for the AT1 subtype and BIBS 222 37 times. BIBS 39 shifts the All concentration-contractile response curves in isolated rabbit aorta to the right in a parallel fashion. [1]in vivo: In pithed rats, BIBS 39 dependently shifts the dose-response curve of All to the right without affecting the maximal response. BIBS 222

also causes parallel shifts to the right but a significant reduction of the maximal responses was observed at 3 and 10 mg/kg i.v. These results show that the benzimidazole derivatives BIBS 39 is a potent and selective All receptor antagonists. Substitution with a benzimidazole moiety results into a considerable loss of selectivity for the AT1 receptor subtype compared with an imidazole moiety as, for instance, in DuP 753.[1] BIBS 39 is a new nonpeptide angiotensin receptor blockers that has affinity for both AT1- and AT2-receptors, is also a potent antagonist of the cardiovascular effects of All in pithed rabbits. [2]

REFERENCES

- [1]. Zhang J, et al. Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. *Eur J Pharmacol.* 1992 Jul 21;218(1):35-41.
- [2]. Zhang J, et al. Hemodynamic effects of angiotensin II and the influence of angiotensin receptor antagonists in pithed rabbits. *J Cardiovasc Pharmacol.* 1995 May;25(5):724-31.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA